This site is intended for healthcare professionals
FDA Hero Banner - Multi-coloured pills and tablets
FDA Drug information

Doxycycline Hyclate

Read time: 1 mins
Marketing start date: 28 Apr 2024
...
 

Summary of product characteristics


Effective Time

20221013

Version

2

Spl Product Data Elements

Doxycycline Hyclate Doxycycline Hyclate DOXYCYCLINE HYCLATE DOXYCYCLINE ANHYDROUS ANHYDROUS LACTOSE CELLULOSE, MICROCRYSTALLINE CROSPOVIDONE HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST) HYPROMELLOSES LACTOSE MONOHYDRATE SODIUM CHLORIDE SODIUM LAURYL SULFATE STARCH, CORN STEARIC ACID TALC TRIETHYL CITRATE WHITE TO OFF-WHITE OVAL 70;8 Doxycycline Hyclate Doxycycline Hyclate DOXYCYCLINE HYCLATE DOXYCYCLINE ANHYDROUS ANHYDROUS LACTOSE CELLULOSE, MICROCRYSTALLINE CROSPOVIDONE HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST) HYPROMELLOSES LACTOSE MONOHYDRATE SODIUM CHLORIDE SODIUM LAURYL SULFATE STARCH, CORN STEARIC ACID TALC TRIETHYL CITRATE WHITE TO OFF-WHITE OVAL 70;9 Doxycycline Hyclate Doxycycline Hyclate DOXYCYCLINE HYCLATE DOXYCYCLINE ANHYDROUS ANHYDROUS LACTOSE CELLULOSE, MICROCRYSTALLINE CROSPOVIDONE HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST) HYPROMELLOSES LACTOSE MONOHYDRATE SODIUM CHLORIDE SODIUM LAURYL SULFATE STARCH, CORN STEARIC ACID TALC TRIETHYL CITRATE WHITE TO OFF-WHITE CAPSULE 7;1;0

Application Number

ANDA206772

Brand Name

Doxycycline Hyclate

Generic Name

Doxycycline Hyclate

Product Ndc

70771-1587

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1587-6 in bottle of 60 tablets Doxycycline Hyclate Delayed-release Tablets USP, 75 mg Rx only 60 tablets NDC 70771-1588-6 in bottle of 60 tablets Doxycycline Hyclate Delayed-release Tablets USP, 100 mg Rx only 60 tablets NDC 70771-1589-6 in bottle of 60 tablets Doxycycline Hyclate Delayed-release Tablets USP, 150 mg Rx only 60 tablets 75 mg label 100 mg label 150 mg label

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.